Aptinyx to Present at 37th Annual J.P. Morgan Healthcare Conference

EVANSTON, Ill., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. APTX, a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Norbert Riedel, Ph.D., president and CEO, will present at the 37^th Annual J.P. Morgan Healthcare Conference. The presentation will take place on Tuesday, January 8^th, 2019 at 4:00 p.m. PST at the Westin St. Francis Hotel in San Francisco.

A live audio webcast of the event will be available on the Investors & Media section of Aptinyx's website at https://ir.aptinyx.com. A replay of the webcast will be archived on Aptinyx's website for up to 30 days following the event.

About Aptinyx
Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders. Aptinyx has a platform for the discovery of novel compounds that work through a unique mechanism to modulate – rather than block or over-activate – NMDA receptors and enhance synaptic plasticity, the foundation of neural cell communication. The company has three product candidates in clinical development in central nervous system indications, including chronic pain, post-traumatic stress disorder, and cognitive impairment associated with Parkinson's disease. Aptinyx is also advancing additional compounds from its proprietary discovery platform, which continues to generate a rich and diverse pipeline of small-molecule NMDA receptor modulators with the potential to treat an array of neurologic disorders. For more information, visit www.aptinyx.com.

Investor Contacts:
Nick Smith
Aptinyx Inc.
ir@aptinyx.com
847-871-0377

Rachel Frank
Stern Investor Relations
rachelf@sternir.com
212-362-1200

Media Contact:
Jordann Phillips
Canale Communications
jordann@canalecomm.com
619-849-6009

Source: Aptinyx Inc.